ASKA Pharmaceutical Holdings Co.,Ltd.
Stock Price Chart
2026/07/15 UpdatedPrice Trend
2026/07/15 UpdatedPrice & Trading Details
2026/07/15 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/07/01Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2024/08/04 | ¥43.80 | ¥44.95 | +2.6% |
| 2016/02/03 | ¥29.16 | ¥24.54 | -15.9% |
| 2015/08/02 | ¥24.26 | ¥6.72 | -72.3% |
| 2015/05/11 | ¥-12.19 | ¥-10.37 | +14.9% |
Shareholder Composition
Updated 2026/07/01Major Holders
Updated 2026/07/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
DFA International Small Cap Value Portfolio
|
353.2K | +2.29% | |
|
Vanguard International Stock Index-Total Intl Stock Indx
|
207.9K | 0.00% | |
|
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund
|
177.2K | +14.17% | |
|
DFA Japanese Small Company Series
|
130.7K | 0.00% | |
|
DFA International Core Equity Portfolio
|
125.9K | 0.00% | |
|
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index
|
67.8K | 0.00% |
Dividend History
Updated 2026/07/12| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥33 | -42.1% |
| 2025 | ¥57 | +26.7% |
| 2024 | ¥45 | +60.7% |
| 2023 | ¥28 | +75.0% |
| 2022 | ¥16 | - |
Financial Performance
2026/07/12 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥60,461M | ¥62,843M | ¥64,139M | ¥71,127M |
| Gross Profit | ¥28,584M | ¥30,664M | ¥31,335M | ¥34,145M |
| Operating Income | ¥5,108M | ¥6,500M | ¥5,332M | ¥5,834M |
| Pretax Income | ¥5,407M | ¥9,902M | ¥6,243M | ¥7,213M |
| Net Income | ¥4,238M | ¥7,545M | ¥5,101M | ¥5,424M |
| EPS | ¥150.08 | ¥266.51 | ¥179.95 | ¥191.12 |
| Operating Margin | 8.45% | 10.34% | 8.31% | 8.20% |
| Balance Sheet | ||||
| Total Assets | ¥87,138M | ¥90,745M | ¥104,295M | ¥112,379M |
| Total Equity | ¥54,531M | ¥61,929M | ¥65,309M | ¥70,359M |
| Total Liabilities | ¥32,607M | ¥28,816M | ¥38,986M | ¥42,020M |
| Cash | ¥14,505M | ¥13,738M | ¥10,603M | ¥10,126M |
| Interest-bearing Debt | ¥12,623M | ¥9,485M | ¥10,902M | ¥11,434M |
| Equity Ratio | 62.58% | 68.25% | 62.62% | 62.61% |
| D/E Ratio | 0.23 | 0.15 | 0.17 | 0.16 |
| Cash Flow | ||||
| Operating CF | ¥3,351M | ¥1,486M | ¥2,485M | ¥6,303M |
| Investing CF | -¥1,126M | ¥1,706M | -¥6,124M | -¥5,752M |
| Financing CF | -¥1,820M | -¥3,943M | -¥2,956M | -¥818M |
| Free CF | ¥2,605M | ¥33M | -¥1,077M | ¥3,429M |
| Efficiency | ||||
| ROE | 7.77% | 12.18% | 7.81% | 7.71% |
| ROA | 4.86% | 8.31% | 4.89% | 4.83% |
Latest IR Information
-
[Asuka Pharmaceutical] Share Buyback and Revision of Executive Compensation System | July 2026
Asuka Pharmaceutical announced on August 12, 2026, the disposal of 53,600 common shares at 2,259 yen per share, along with a partial revision of the executive compensation system and the introduction of long-term incentives.
Read more -
【Asuka Pharmaceutical】Share Buyback for Employee Shareholding Association | November 2, 2026
Asuka Pharmaceutical will transfer 22,198 shares of treasury stock to the employee shareholding association, with a disposal price of ¥2,259 per share, totaling approximately ¥50.1 million. The system aims to enhance employee engagement and improve corporate value over the medium...
Read more -
Notice of Results of the 5th Annual Shareholders Meeting
Asuka Pharmaceutical Holdings held its 5th Annual Shareholders Meeting, with all proposals approved by a majority of votes. Under new management, the company outlined policies aimed at sustainable growth and enhancing corporate value.
Read more -
Notice of Amendments to the Articles of Incorporation | June 24, 2026
Asuka Pharmaceutical plans to approve the amendment of the Articles of Incorporation and transition to a Company with Audit & Supervisory Committee at the shareholders' meeting scheduled for June 24, 2026. This aims to enhance management transparency and accelerate decision-making.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,400
Rating Score: 3.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and other businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and researches, manufactures, imports, exports, and sells veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers quasi-drugs, food supplements, and medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
